AgeneBio

AgeneBio is a neuroscience pharmaceutical company developing treatments for diseases that impact memory.

AgeneBio is a neuroscience pharmaceutical company founded by Dr Michela Gallagher in 2008 that is focused on developing treatments for diseases that impact memory. The initial therapeutic targets are Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). The company is headquartered in Indianapolis but conducts research and development work on a global basis utilizing partner relationships.